Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.

Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT.

Cancer Med. 2020 Mar;9(6):2039-2051. doi: 10.1002/cam4.2741. Epub 2020 Jan 28.

2.

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Holmström MO, Cordua S, Skov V, Kjær L, Pallisgaard N, Ellervik C, Hasselbalch HC, Andersen MH.

Cancer Immunol Immunother. 2020 Feb;69(2):315-324. doi: 10.1007/s00262-019-02473-y. Epub 2020 Jan 8. Review.

PMID:
31915854
3.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC.

Haematologica. 2019 Dec 26. pii: haematol.2019.235648. doi: 10.3324/haematol.2019.235648. [Epub ahead of print]

4.

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C.

Blood. 2019 Aug 1;134(5):469-479. doi: 10.1182/blood.2019001113. Epub 2019 Jun 19. Erratum in: Blood. 2019 Oct 3;134(14):1195.

PMID:
31217187
5.

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG.

Ann Oncol. 2019 Jul 1;30(7):1088-1095. doi: 10.1093/annonc/mdz139.

6.

Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.

Kjaer L, Skov V, Andersen MT, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MH, Hasselbalch H, Pallisgaard N.

Eur J Haematol. 2019 Jul;103(1):26-34. doi: 10.1111/ejh.13238. Epub 2019 May 1.

PMID:
30985947
7.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH.

Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4.

8.

Bridging blood cancers and inflammation: The reduced Cancitis model.

Ottesen JT, Pedersen RK, Sajid Z, Gudmand-Hoeyer J, Bangsgaard KO, Skov V, Kjær L, Knudsen TA, Pallisgaard N, Hasselbalch HC, Andersen M.

J Theor Biol. 2019 Mar 21;465:90-108. doi: 10.1016/j.jtbi.2019.01.001. Epub 2019 Jan 4.

PMID:
30615883
9.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

10.

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.

Spindler KG, Demuth C, Sorensen BS, Johansen JS, Nielsen D, Pallisgaard N, Hoegdall E, Pfeiffer P, Vittrup Jensen B.

Tumour Biol. 2018 Nov;40(11):1010428318811207. doi: 10.1177/1010428318811207.

PMID:
30486767
11.

Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer.

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL.

Clin Chim Acta. 2018 Dec;487:107-111. doi: 10.1016/j.cca.2018.09.029. Epub 2018 Sep 18.

PMID:
30240586
12.

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing.

Demuth C, Spindler KG, Johansen JS, Pallisgaard N, Nielsen D, Hogdall E, Vittrup B, Sorensen BS.

Transl Oncol. 2018 Oct;11(5):1220-1224. doi: 10.1016/j.tranon.2018.07.013. Epub 2018 Aug 4.

13.

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.

Link-Lenczowska D, Pallisgaard N, Cordua S, Zawada M, Czekalska S, Krochmalczyk D, Kanduła Z, Sacha T.

Ann Hematol. 2018 Dec;97(12):2299-2308. doi: 10.1007/s00277-018-3451-1. Epub 2018 Jul 28.

14.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC.

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.

15.

Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.

Hamfjord J, Guren T, Dajani O, Glimelius B, Sorbye H, Pfeiffer P, Christoffersen T, Lingjærde O, Tveit K, Kure E, Pallisgaard N, Spindler K.

Ann Oncol. 2018 Jun;29 Suppl 5:v109. doi: 10.1093/annonc/mdy149.025. Epub 2020 Jan 7. No abstract available.

16.

Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.

Kodahl AR, Ehmsen S, Pallisgaard N, Jylling AMB, Jensen JD, Laenkholm AV, Knoop AS, Ditzel HJ.

Mol Oncol. 2018 Jun;12(6):925-935. doi: 10.1002/1878-0261.12305. Epub 2018 May 4.

17.

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V, Kjær L, Pallisgaard N, Kruse TA, Thomassen M, Troelsen J, Hasselbalch HC, Ottesen JT.

PLoS One. 2017 Aug 31;12(8):e0183620. doi: 10.1371/journal.pone.0183620. eCollection 2017.

18.

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC.

Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. No abstract available.

PMID:
28792253
19.

The Danish National Chronic Myeloid Neoplasia Registry.

Bak M, Ibfelt EH, Stauffer Larsen T, Rønnov-Jessen D, Pallisgaard N, Madelung A, Udby L, Hasselbalch HC, Bjerrum OW, Andersen CL.

Clin Epidemiol. 2016 Oct 25;8:567-572. eCollection 2016. Review.

20.

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Kjær L, Cordua S, Holmström MO, Thomassen M, Kruse TA, Pallisgaard N, Larsen TS, de Stricker K, Skov V, Hasselbalch HC.

PLoS One. 2016 Oct 20;11(10):e0165336. doi: 10.1371/journal.pone.0165336. eCollection 2016.

21.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

22.

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

Eriksen AH, Andersen RF, Pallisgaard N, Sørensen FB, Jakobsen A, Hansen TF.

PLoS One. 2016 Mar 3;11(3):e0150593. doi: 10.1371/journal.pone.0150593. eCollection 2016.

23.

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

Spindler KL, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, Pfeiffer P, Yilmaz M, Johansen JS, Hoegdall EV, Jakobsen A, Jensen BV.

Eur J Cancer. 2015 Nov;51(17):2678-85. doi: 10.1016/j.ejca.2015.06.118. Epub 2015 Oct 24.

PMID:
26508156
24.

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification.

Sørensen PD, Andersen RF, Pallisgaard N, Madsen JS, Jakobsen EH, Brandslund I.

J Circ Biomark. 2015 Aug 31;4:9. doi: 10.5772/61320. eCollection 2015 Jan-Dec.

25.

Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter.

Kodahl AR, Pallisgaard N, Jylling AM, Cold S, Knoop AS, Ditzel HJ.

Clin Cancer Res. 2015 Aug 1;21(15):3569. doi: 10.1158/1078-0432.CCR-15-0776. No abstract available.

26.

[New disease markers within the chronic myeloproliferative neoplasms].

Holmström MO, Ocias LF, Kallenbach K, Kjær L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker K, Larsen TS, Hasselbalch HC.

Ugeskr Laeger. 2015 May 4;177(19). pii: V12140653. Review. Danish.

PMID:
25967091
27.

Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Review.

PMID:
25951317
28.

Controls to validate plasma samples for cell free DNA quantification.

Pallisgaard N, Spindler KL, Andersen RF, Brandslund I, Jakobsen A.

Clin Chim Acta. 2015 Jun 15;446:141-6. doi: 10.1016/j.cca.2015.04.015. Epub 2015 Apr 18.

PMID:
25896958
29.

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.

Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

PLoS One. 2015 Apr 13;10(4):e0108247. doi: 10.1371/journal.pone.0108247. eCollection 2015.

30.

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Ørntoft TF, Andersen CL.

Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.

PMID:
25654990
31.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A.

Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Review.

32.

Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons.

Andersen RF, Spindler KL, Brandslund I, Jakobsen A, Pallisgaard N.

Clin Chim Acta. 2015 Jan 15;439:97-101. doi: 10.1016/j.cca.2014.10.011. Epub 2014 Oct 20.

PMID:
25446878
33.

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.

Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

Int J Cancer. 2014 Dec 15;135(12):2984-91. doi: 10.1002/ijc.28946. Epub 2014 Jun 17.

34.

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Int J Cancer. 2014 Nov 1;135(9):2215-22. doi: 10.1002/ijc.28863. Epub 2014 Apr 17.

35.

Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Br J Cancer. 2014 Dec 9;111(12):2380. doi: 10.1038/bjc.2014.115. Epub 2014 Mar 11. No abstract available.

36.

Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.

Spindler KL, Pallisgaard N, Andersen RF, Ploen J, Jakobsen A.

Anticancer Res. 2014 Feb;34(2):845-50.

PMID:
24511021
37.

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

Dowler Nygaard A, Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Oncol Rep. 2014 Feb;31(2):969-74. doi: 10.3892/or.2013.2906. Epub 2013 Dec 6.

PMID:
24316734
38.

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.

Spindler KG, Appelt AL, Pallisgaard N, Andersen RF, Jakobsen A.

Br J Cancer. 2013 Dec 10;109(12):3067-72. doi: 10.1038/bjc.2013.633. Epub 2013 Nov 21.

39.

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.

Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A.

Br J Cancer. 2014 Jan 21;110(2):363-8. doi: 10.1038/bjc.2013.705. Epub 2013 Nov 14.

40.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

41.

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.

Spindler KL, Sorensen MM, Pallisgaard N, Andersen RF, Havelund BM, Ploen J, Lassen U, Jakobsen AK.

Acta Oncol. 2013 Jun;52(5):963-70. doi: 10.3109/0284186X.2013.776175. Epub 2013 Mar 20.

PMID:
23514584
42.

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.

Bechmann T, Andersen RF, Pallisgaard N, Madsen JS, Maae E, Jakobsen EH, Bak Jylling AM, Steffensen KD, Jakobsen A.

J Cancer Res Clin Oncol. 2013 Jun;139(6):995-1003. doi: 10.1007/s00432-013-1413-5. Epub 2013 Mar 12.

PMID:
23479212
43.

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Lung Cancer. 2013 Mar;79(3):312-7. doi: 10.1016/j.lungcan.2012.11.016. Epub 2012 Dec 11.

PMID:
23238036
44.

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A.

Clin Cancer Res. 2012 Feb 15;18(4):1177-85. doi: 10.1158/1078-0432.CCR-11-0564. Epub 2012 Jan 6.

45.

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.

Østergaard M, Nyvold CG, Jovanovic JV, Andersen MT, Kairisto V, Morgan YG, Tobal K, Pallisgaard N, Ozbek U, Pfeifer H, Schnittger S, Grubach L, Larsen JK, Grimwade D, Hokland P.

Leukemia. 2011 Jul;25(7):1168-73. doi: 10.1038/leu.2011.69. Epub 2011 Apr 15.

PMID:
21494256
46.

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.

Spindler KL, Pallisgaard N, Lindebjerg J, Frifeldt SK, Jakobsen A.

BMC Cancer. 2011 Mar 25;11:107. doi: 10.1186/1471-2407-11-107.

47.

[Eosinophilia--pathogenesis, classification and therapy].

Andersen CL, Vestergaard H, Nørgaard P, Felding P, Pallisgaard N, Rasmussen IH, Hasselbalch HC, Bjerrum OW.

Ugeskr Laeger. 2009 Nov 2;171(45):3256-62. Review. Danish.

PMID:
19887055
48.

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, Jakobsen A.

Ann Oncol. 2009 May;20(5):879-84. doi: 10.1093/annonc/mdn712. Epub 2009 Jan 29.

49.

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.

Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC.

Hematology. 2009 Feb;14(1):11-5. doi: 10.1179/102453309X385188.

PMID:
19154659
50.

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Hematology. 2008 Apr;13(2):71-6. doi: 10.1179/102453308X315960.

PMID:
18616871

Supplemental Content

Loading ...
Support Center